EUCTR2009-012010-52-DK进行中（未招募）1 期
Bevacizumab, Interleukin-2 and Interferon-alpha in metastathic renal cell carcinoma - mRCC
Department of Oncology, Aarhus University Hospital0 个研究点目标入组 118 人开始时间: 2009年5月28日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 118
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Signed written informed consent obtained prior to any study specific screening procedures.
- •2.Patient must be willing and able to comply with the protocol.
- •3.Age ? 18.
- •4.Histologic og cytologic biopsy proven locally advanced or metastatic renal cell carcinoma, considered non-candidates for curative surgery. Nephrectomy is not mandatory.
- •5.Patient with renal cell carcinoma (RCC) with a clear-cell histologic component confirmed by local pathology review. (Patient with true papillary, sarcomatoid features without any clear cell component, chromophobe, oncocytoma, collecting duct tumours, Bellini tumours and transitional cell carcinoma are not allowed.)
- •6.If metastatic disease is diagnosed more than two years from the date of the initial diagnosis of RCC, histological or cytological confirmation of renal cell carcinoma (clear cell type) origin of the metastatic lesion(s) is mandatory.
- •7.Females with a negative serum pregnancy test unless childbearing potential can be otherwise excluded (postmenopausal, hysterectomy or oophorectomy) and not lactating.
- •8.Fertile women of childbearing potential (<2 years after last menstruation) and men must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgical sterilisation).
- •9.Memorial-Sloan-Kettering-Cancer-Centre favourable- and intermediate prognostic group.
- •10.Measurable or non-measurable disease (as per RECIST criteria)
- •11.Karnofsky Performance status ? 70%.
- •12.Life expectancy greater than 4 months.
- •13.The required laboratory values at baseline are as follows:
- •14.Haematology:
- •15.WCC = 3.0 x 109/L, Platelet count = 100 x 109/L, Haemoglobin = 6.2 mmol/l, International Normalized Ratio (INR) = 1.5, APTT = 1.5 x ULN
- •16.Biochemistry:
- •Total bilirubin = 1.5 x upper limit of normal (ULN), AST, ALT = 2.5 x ULN in patients without liver metastases, = 5 x ULN in patients with liver metastases, Serum Creatinine = 150 ?mol/L
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Prior systemic treatment for metastatic RCC disease (including neo-adjuvant therapy).
- •2.Major surgical procedure, open surgical biopsy, or significant traumatic injury within 28 days prior to randomization.
- •3.Serious non-healing wound, ulcer or bone fracture.
- •4.Evidence of current central nervous system (CNS) metastases or spinal cord compression. Patient must undergo an MRI or CT scan of the brain (with contrast, if possible) within 28 days prior to randomization.
- •5.Seizure(s) not controlled with standard medical therapy.
- •6.Dipstick urine test of protein = 2+.
- •7.Other malignancies within 5 years prior to randomization (other than curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix).
- •8.Evidence of bleeding diathesis or coagulopathy.
- •9.Ongoing or recent (within 10 days prior to study treatment start) need for full therapeutic dose of oral anticoagulants or chronic daily treatment with aspirin. Low molecular weight heparin are allowed
- •10.Uncontrolled hypertension (? 160 mm Hg systolic and/or ? 100 mm Hg diastolic) while receiving chronic medication.
- •11.Clinically significant (i.e. active) cardiovascular disease, for example cerebrovascular accidents (= 6 months before randomisation), myocardial infarction (= 6 months before randomisation), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication.
- •12.Recent (within the 30 days prior to randomization) treatment with another investigational drug or participation in another investigational study.
- •13.Chronic treatment with corticosteroids (dose of = 10 mg/day methylprednisolone equivalent), excluding inhaled steroids.
- •14.History or presence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or patient at high risk from treatment complications.
- •15.Known hypersensitivity to interleukin-2, Inferferon, alpha or bevacizumab.
研究者
相似试验
进行中（未招募）
不适用
Bevacizumab (Avastin™), dacarbazine and interferon a-2a (Roferon-A; IFN a-2a ) combination as a first-line therapy in patients with locally advancing or metastatic melanomaPatients with histologically confirmed metastatic melanomaEUCTR2005-001316-47-FITurku University Central Hospital40
进行中（未招募）
1 期
Antiviral and Immunomodulatory Interferon-Beta in high-risk COVID-19 patientsSARS-CoV 2 infection characterized by a National Early Warning Score lower or equal to 2 and symptoms present for less than 7 daysMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862MedDRA version: 20.0Level: PTClassification code 10070255Term: Coronavirus test positiveSystem Organ Class: 10022891 - InvestigationsEUCTR2020-003872-42-ITIstituto di Farmacologia Traslazionale - CNR60
终止
2 期
Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney CancerCarcinoma, Renal CellNCT00440973The Methodist Hospital Research Institute6
已完成
3 期
Adjuvant interleukin-2, interferon-alpha and 5-fluorouracil for patients with high risk of relapse after surgical treatment for renal cell carcinomaCancer, kidneyKidneyCancerISRCTN16387614Cancer Research UK (CRUK) (UK)214
进行中（未招募）
不适用
Treatment with Peg-interferon alfa-2a and ribavirin in patients with hepatitis HCV-related, with or without HIV co-infection, and end stage renal disease on dialysis - NDChonic hepatitis HCV-relatedMedDRA version: 9.1Level: SOCClassification code 10019805MedDRA version: 9.1Level: SOCClassification code 10038359EUCTR2010-023245-30-ITISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI